Recent KRBP News
- Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients • Business Wire • 04/24/2024 12:08:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/19/2024 08:30:26 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 04/10/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/05/2024 08:30:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2024 08:30:20 PM
- Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial • Business Wire • 04/02/2024 12:18:00 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 03/21/2024 09:21:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2024 09:58:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2024 09:57:02 PM
- Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial • Business Wire • 03/19/2024 12:08:00 PM
- Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial • Business Wire • 03/01/2024 01:08:00 PM
- Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th • Business Wire • 02/28/2024 11:30:00 PM
- Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th • GlobeNewswire Inc. • 02/28/2024 09:09:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:30:45 PM
- Results from First Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months • Business Wire • 02/14/2024 01:08:00 PM
- Kiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer • Business Wire • 01/29/2024 12:47:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/11/2024 09:15:21 PM
- Kiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial • Business Wire • 01/05/2024 01:08:00 PM
- Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer • Business Wire • 12/14/2023 01:17:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 02:49:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 08:45:22 PM
- Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14 • Business Wire • 09/13/2023 08:35:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/29/2023 08:15:48 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/15/2023 08:16:11 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:52:28 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM